Brewin Dolphin's Q3 2021: Quarterly Review

Strong growth in profits provided a boost to company shares during the third quarter of 2021, but anxiety over the future tempered those gains. In their recent report, Criticaleye Advisory Member, Brewin Dolphin, looks back at the events that have shaped markets over the past three months and highlight what to expect in 2022. 
 
Key takeaways include:
  • Some of the supply shortages can be blamed on companies that misjudged what lockdown would mean, in terms of goods demand.
  • ‘Upstream’ oil prices have been rising but, towards the end of the quarter, oil availability became an even greater problem ‘downstream’, as a shortage of HGV drivers made it difficult to get petrol to filling stations.
  • Going into 2022, it seems likely that monetary policy will tighten.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

The Inspiring Leaders Podcast...

Focused on what leaders should be prioritising over the next twelve months, advice for first-time CEOs and how Chairs in high-growth businesses can better support their CEOs. Key discussion points include: Pr...

Click here to download this insight
True Diligence: Preparing for...

In the face of escalating societal demands, intensified stakeholder scrutiny and expanding global regulatory requirements, the pressure is on for businesses to assume their collective responsibility towards both people ...

Click here to download this insight
Cultural Integration in M&A

Most economists are predicting higher volumes for M&A over the next 12 months, albeit coming off a low base. In this article, Criticaleye’s Jacob Ambrose Willson hears from Matthew Parker, CEO of the highly ac...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 2,064




Royal London Group Salesforce Legal & General Investment Management E.ON UK Google Eightfold AI Tullow Oil plc Workday Accenture Amazon UK London Stock Exchange Redwood Bank Eton Bridge Partners Concentrix + Webhelp Lightsource bp Mayborn Group Drax Group plc Veolia Water Technologies AlixPartners Robert Walters GlaxoSmithKline plc LDC Bunzl plc NATS